Artykuły w czasopismach na temat „PTC mutation”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „PTC mutation”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Liu, Xiaoli, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K. El-Naggar i Mingzhao Xing. "Highly prevalent TERT promoter mutations in aggressive thyroid cancers". Endocrine-Related Cancer 20, nr 4 (13.06.2013): 603–10. http://dx.doi.org/10.1530/erc-13-0210.
Pełny tekst źródłaRusinek, Dagmara, Aleksandra Pfeifer, Jolanta Krajewska, Malgorzata Oczko-Wojciechowska, Daria Handkiewicz-Junak, Agnieszka Pawlaczek, Jadwiga Zebracka-Gala i in. "Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients". International Journal of Molecular Sciences 19, nr 9 (6.09.2018): 2647. http://dx.doi.org/10.3390/ijms19092647.
Pełny tekst źródłaClarke, Luka A., Vanessa C. C. Luz, Szymon Targowski, Sofia S. Ramalho, Carlos M. Farinha i Margarida D. Amaral. "Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis". Genes 12, nr 11 (18.11.2021): 1810. http://dx.doi.org/10.3390/genes12111810.
Pełny tekst źródłaHenke, Lauren E., John D. Pfeifer, Thomas J. Baranski, Todd DeWees i Perry W. Grigsby. "Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma". Endocrine Connections 7, nr 12 (grudzień 2018): 1226–35. http://dx.doi.org/10.1530/ec-18-0264.
Pełny tekst źródłaChoi, Yun-Suk, Seong-Woon Choi i Jin-Wook Yi. "Prospective Analysis of TERT Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution". Journal of Clinical Medicine 10, nr 10 (18.05.2021): 2179. http://dx.doi.org/10.3390/jcm10102179.
Pełny tekst źródłaLiu, Jie, Huizheng Li, Rong Du, Nan Fang, Jingbo Zhang, Yu Tang, Jianwei Wang i Qixi Wu. "Targeted next-generation sequencing in papillary thyroid carcinoma of Chinese Han population." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): e17574-e17574. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e17574.
Pełny tekst źródłaChakraborty, Dhritiman, Sunil Shakya, Sanjana Ballal, Shipra Agarwal i Chandrasekhar Bal. "BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation". Journal of Pediatric Endocrinology and Metabolism 33, nr 11 (26.11.2020): 1465–74. http://dx.doi.org/10.1515/jpem-2020-0174.
Pełny tekst źródłaBarzon, Luisa, Giulia Masi, Isabella Merante Boschin, Enrico Lavezzo, Monia Pacenti, Eric Casal Ide, Antonio Toniato, Stefano Toppo, Giorgio Palù i Maria Rosa Pelizzo. "Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma." European Journal of Endocrinology 159, nr 1 (lipiec 2008): 77–80. http://dx.doi.org/10.1530/eje-08-0239.
Pełny tekst źródłaSiraj, Sarah, Tariq Masoodi, Abdul K. Siraj, Saud Azam, Zeeshan Qadri, Sandeep K. Parvathareddy, Rong Bu i in. "APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma". Cancers 14, nr 6 (21.03.2022): 1584. http://dx.doi.org/10.3390/cancers14061584.
Pełny tekst źródłaDurand, Stéphanie, Carole Ferraro-Peyret, Mireille Joufre, Annie Chave, Françoise Borson-Chazot, Samia Selmi-Ruby i Bernard Rousset. "Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features". Endocrine-Related Cancer 16, nr 2 (czerwiec 2009): 467–81. http://dx.doi.org/10.1677/erc-08-0081.
Pełny tekst źródłaPamedytyte, Daina, Vaida Simanaviciene, Dalia Dauksiene, Enrika Leipute, Aurelija Zvirbliene, Valdas Sarauskas, Albertas Dauksa, Rasa Verkauskiene i Birute Zilaitiene. "Association of microRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer". Biomolecules 10, nr 4 (17.04.2020): 625. http://dx.doi.org/10.3390/biom10040625.
Pełny tekst źródłaGąsior-Perczak, Danuta, Artur Kowalik, Agnieszka Walczyk, Monika Siołek, Krzysztof Gruszczyński, Iwona Pałyga, Estera Mikina i in. "Coexisting Germline CHEK2 and Somatic BRAFV600E Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course". Cancers 11, nr 11 (7.11.2019): 1744. http://dx.doi.org/10.3390/cancers11111744.
Pełny tekst źródłaJoshi, Tripti, Ruta Gupta, Luisa Fernanda Olaya A, Bing Yu, Susan McLennan i Elizabeth Lian Chua. "Molecular Genetics in a Cohort of Patients With Concurrent PTC and Melanoma". Journal of the Endocrine Society 5, Supplement_1 (1.05.2021): A1027. http://dx.doi.org/10.1210/jendso/bvab048.2102.
Pełny tekst źródłaJin, Meihua, Dong Eun Song, Jonghwa Ahn, Eyun Song, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim i in. "Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas". Cancers 13, nr 4 (20.02.2021): 892. http://dx.doi.org/10.3390/cancers13040892.
Pełny tekst źródłaVidinov, K., R. Dodova, P. Mitev, A. Mitkova, I. Dimitrova, A. Shinkov, R. Ivanova, V. Mitev i R. Kaneva. "Clinicopathological Significance of BRAF (V600E), NRAS (Q61K) and TERT (C228T, C250T and SNP Rs2853669) Mutations in Bulgarian Papillary Thyroid Carcinoma Patients". Acta Medica Bulgarica 48, nr 1 (1.04.2021): 1–8. http://dx.doi.org/10.2478/amb-2021-0001.
Pełny tekst źródłaKarunamurthy, Arivarasan, Federica Panebianco, Susan J. Hsiao, Jennie Vorhauer, Marina N. Nikiforova, Simion Chiosea i Yuri E. Nikiforov. "Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules". Endocrine-Related Cancer 23, nr 4 (kwiecień 2016): 295–301. http://dx.doi.org/10.1530/erc-16-0043.
Pełny tekst źródłaLupi, Cristiana, Riccardo Giannini, Clara Ugolini, Agnese Proietti, Piero Berti, Michele Minuto, Gabriele Materazzi i in. "Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma". Journal of Clinical Endocrinology & Metabolism 92, nr 11 (1.11.2007): 4085–90. http://dx.doi.org/10.1210/jc.2007-1179.
Pełny tekst źródłaHardee, Steven, Manju L. Prasad, Pei Hui, Catherine A. Dinauer i Raffaella A. Morotti. "Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma". Pediatric and Developmental Pathology 20, nr 3 (8.02.2017): 206–12. http://dx.doi.org/10.1177/1093526616689628.
Pełny tekst źródłaEbina, Aya, Yuki Togashi, Satoko Baba, Yukiko Sato, Seiji Sakata, Masashi Ishikawa, Hiroki Mitani, Kengo Takeuchi i Iwao Sugitani. "TERT Promoter Mutation and Extent of Thyroidectomy in Patients with 1–4 cm Intrathyroidal Papillary Carcinoma". Cancers 12, nr 8 (30.07.2020): 2115. http://dx.doi.org/10.3390/cancers12082115.
Pełny tekst źródłaPlaksa, I. L., M. R. Savchuk, N. V. Shved, N. A. Savelov, D. N. Khmelkova, А. A. Isaev i R. V. Deev. "Mutation profile of the tall cell variant of papillary thyroid carcinoma: analysis of 5 cases using wide-panel next-generation sequencing". Head and Neck Tumors (HNT) 11, nr 1 (24.04.2021): 78–85. http://dx.doi.org/10.17650/2222-1468-2021-11-1-78-85.
Pełny tekst źródłaGertz, Ryan J., Yuri Nikiforov, William Rehrauer, Lee McDaniel i Ricardo V. Lloyd. "Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population". Archives of Pathology & Laboratory Medicine 140, nr 2 (1.02.2016): 134–39. http://dx.doi.org/10.5858/arpa.2014-0612-oa.
Pełny tekst źródłaWei, Xiaojing, Xiaodong Wang, Jie Xiong, Chen Li, Yixuan Liao, Yongjun Zhu i Jingxin Mao. "Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma". BioMed Research International 2022 (18.05.2022): 1–13. http://dx.doi.org/10.1155/2022/9959649.
Pełny tekst źródłaLin, Xiaoqi, Sydney D. Finkelstein, Bing Zhu i Jan F. Silverman. "Molecular analysis of multifocal papillary thyroid carcinoma". Journal of Molecular Endocrinology 41, nr 4 (15.07.2008): 195–203. http://dx.doi.org/10.1677/jme-08-0063.
Pełny tekst źródłaEspiritu, Gerard Anthony M., Joemari T. Malana, Arlie Jean Grace V. Dumasis i Daphne C. Ang. "High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study". Journal of Global Oncology, nr 5 (grudzień 2019): 1–6. http://dx.doi.org/10.1200/jgo.18.00085.
Pełny tekst źródłaXing, Mingzhao, Douglas Clark, Haixia Guan, Meiju Ji, Alan Dackiw, Kathryn A. Carson, Matthew Kim i in. "BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Biopsy Specimens for Preoperative Risk Stratification in Papillary Thyroid Cancer". Journal of Clinical Oncology 27, nr 18 (20.06.2009): 2977–82. http://dx.doi.org/10.1200/jco.2008.20.1426.
Pełny tekst źródład’Aquino, Anne E., Tasfia Azim, Nikolay A. Aleksashin, Adam J. Hockenberry, Antje Krüger i Michael C. Jewett. "Mutational characterization and mapping of the 70S ribosome active site". Nucleic Acids Research 48, nr 5 (3.02.2020): 2777–89. http://dx.doi.org/10.1093/nar/gkaa001.
Pełny tekst źródłaMuzza, Marina, Gabriele Pogliaghi, Luca Persani, Laura Fugazzola i Carla Colombo. "Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer". Journal of Clinical Medicine 10, nr 12 (16.06.2021): 2645. http://dx.doi.org/10.3390/jcm10122645.
Pełny tekst źródłaGuan, Haixia, Meiju Ji, Rong Bao, Hongyu Yu, Yangang Wang, Peng Hou, Yong Zhang, Zhongyan Shan, Weiping Teng i Mingzhao Xing. "Association of High Iodine Intake with the T1799A BRAF Mutation in Papillary Thyroid Cancer". Journal of Clinical Endocrinology & Metabolism 94, nr 5 (1.05.2009): 1612–17. http://dx.doi.org/10.1210/jc.2008-2390.
Pełny tekst źródłaRusinek, Dagmara, Aleksandra Pfeifer, Marta Cieslicka, Malgorzata Kowalska, Agnieszka Pawlaczek, Jolanta Krajewska, Sylwia Szpak-Ulczok i in. "TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma". Cancers 12, nr 6 (17.06.2020): 1597. http://dx.doi.org/10.3390/cancers12061597.
Pełny tekst źródłaHan, Jiheun, Young Lyun Oh i Jung-Sun Kim. "Co-Occurrence of Hotspot Point Mutation and Novel Deletion Mutation of TERT Promoter in Solid Variant Papillary Thyroid Carcinoma in a Patient with Synchronous Esophageal Cancer". Diagnostics 11, nr 1 (22.12.2020): 4. http://dx.doi.org/10.3390/diagnostics11010004.
Pełny tekst źródłaVuong, Huy Gia, Uyen N. P. Duong, Ahmed M. A. Altibi, Hanh T. T. Ngo, Thong Quang Pham, Hung Minh Tran, Greta Gandolfi i Lewis Hassell. "A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma". Endocrine Connections 6, nr 3 (kwiecień 2017): R8—R17. http://dx.doi.org/10.1530/ec-17-0010.
Pełny tekst źródłaXing, Mingzhao, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A. Zeiger, Sara Pai i Justin Bishop. "BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence". Journal of Clinical Oncology 32, nr 25 (1.09.2014): 2718–26. http://dx.doi.org/10.1200/jco.2014.55.5094.
Pełny tekst źródłaBentz, Brandon G., Brian T. Miller, Joseph A. Holden, Leslie R. Rowe i Joel S. Bentz. "B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules". Otolaryngology–Head and Neck Surgery 140, nr 5 (maj 2009): 709–14. http://dx.doi.org/10.1016/j.otohns.2009.01.007.
Pełny tekst źródłaNam, Myungwoo, Woojung Yang, Ju Young Lee, Jaeyoun Choi, Hansol Choi, Eugene Kim, Emma Yu i in. "753 The immune landscape of papillary thyroid cancer and its association with neoantigen landscape and DNA repair gene mutations". Journal for ImmunoTherapy of Cancer 8, Suppl 3 (listopad 2020): A801. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0753.
Pełny tekst źródłaKim, Seo Ki, Jung-Woo Woo, Jun Ho Lee, Inhye Park, Jun-Ho Choe, Jung-Han Kim i Jee Soo Kim. "Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma". Endocrine-Related Cancer 23, nr 1 (16.10.2015): 27–34. http://dx.doi.org/10.1530/erc-15-0408.
Pełny tekst źródłaElisei, Rossella, Clara Ugolini, David Viola, Cristiana Lupi, Agnese Biagini, Riccardo Giannini, Cristina Romei, Paolo Miccoli, Aldo Pinchera i Fulvio Basolo. "BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study". Journal of Clinical Endocrinology & Metabolism 93, nr 10 (1.10.2008): 3943–49. http://dx.doi.org/10.1210/jc.2008-0607.
Pełny tekst źródłaGąsior-Perczak, Danuta, Artur Kowalik, Krzysztof Gruszczyński, Agnieszka Walczyk, Monika Siołek, Iwona Pałyga, Sławomir Trepka i in. "Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma". Cancers 13, nr 3 (26.01.2021): 470. http://dx.doi.org/10.3390/cancers13030470.
Pełny tekst źródłaXing, Mingzhao, Ali S. Alzahrani, Kathryn A. Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei i in. "Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer". Journal of Clinical Oncology 33, nr 1 (1.01.2015): 42–50. http://dx.doi.org/10.1200/jco.2014.56.8253.
Pełny tekst źródłaXing, Mingzhao, William H. Westra, Ralph P. Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J. Rhoden, Kathryn A. Carson i in. "BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer". Journal of Clinical Endocrinology & Metabolism 90, nr 12 (1.12.2005): 6373–79. http://dx.doi.org/10.1210/jc.2005-0987.
Pełny tekst źródłaSapio, Maria Rosaria, Daniela Posca, Giancarlo Troncone, Guido Pettinato, Lucio Palombini, Guido Rossi, Gianfranco Fenzi i Mario Vitale. "Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA)". European Journal of Endocrinology 154, nr 2 (luty 2006): 341–48. http://dx.doi.org/10.1530/eje.1.02072.
Pełny tekst źródłaZatelli, Maria Chiara, Giorgio Trasforini, Stefania Leoni, Gemma Frigato, Mattia Buratto, Federico Tagliati, Roberta Rossi, Luigi Cavazzini, Elio Roti i Ettore C. degli Uberti. "BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies". European Journal of Endocrinology 161, nr 3 (wrzesień 2009): 467–73. http://dx.doi.org/10.1530/eje-09-0353.
Pełny tekst źródłaLi, Ruoxuan, Jiping Hao, Zhao Zhu, Xudong Qiao, Ling Wang i Zubang Zhou. "Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer". BioMed Research International 2021 (1.07.2021): 1–6. http://dx.doi.org/10.1155/2021/9937742.
Pełny tekst źródłaKim, Min Jhi, Jin Kyong Kim, Gi Jeong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Woong Youn Chung, Daham Kim i Kee-Hyun Nam. "TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea". Cancers 14, nr 19 (8.10.2022): 4928. http://dx.doi.org/10.3390/cancers14194928.
Pełny tekst źródłaLiu, Dingxie, Zhi Liu, Stephen Condouris i Mingzhao Xing. "BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells". Journal of Clinical Endocrinology & Metabolism 92, nr 6 (1.06.2007): 2264–71. http://dx.doi.org/10.1210/jc.2006-1613.
Pełny tekst źródłaHińcza, Kinga, Artur Kowalik, Iwona Pałyga, Agnieszka Walczyk, Danuta Gąsior-Perczak, Estera Mikina, Tomasz Trybek i in. "Does the TT Variant of the rs966423 Polymorphism in DIRC3 Affect the Stage and Clinical Course of Papillary Thyroid Cancer?" Cancers 12, nr 2 (12.02.2020): 423. http://dx.doi.org/10.3390/cancers12020423.
Pełny tekst źródłaM S, Bhuvitha, i Krishna G. "BRAFV600E Mutation in Papillary Carcinoma Thyroid". Annals of Pathology and Laboratory Medicine 9, nr 6 (9.07.2022): A102–108. http://dx.doi.org/10.21276/apalm.3167.
Pełny tekst źródłaKocsis-Deák, Barbara, Kristóf Árvai, Bernadett Balla, Bálint Tóbiás, Andrea Kohánka, Balázs Járay, János Horányi i in. "Targeted Mutational Profiling and a Powerful Risk Score as Additional Tools for the Diagnosis of Papillary Thyroid Cancer". Pathology & Oncology Research 26, nr 1 (22.11.2019): 101–8. http://dx.doi.org/10.1007/s12253-019-00772-4.
Pełny tekst źródłaRasquin, Lorena, Janna Prater, Jane Mayrin i Corrado Minimo. "Simultaneous Pheochromocytoma, Paraganglioma, and Papillary Thyroid Carcinoma without Known Mutation". Case Reports in Endocrinology 2018 (14.10.2018): 1–3. http://dx.doi.org/10.1155/2018/6358485.
Pełny tekst źródłaZhang, Junru. "BRAF gene mutation and papillary thyroid carcinoma". Highlights in Science, Engineering and Technology 14 (29.09.2022): 134–43. http://dx.doi.org/10.54097/hset.v14i.1602.
Pełny tekst źródłaZhu, Guoquan, Yuying Deng, Liqin Pan, Wei Ouyang, Huijuan Feng, Juqing Wu, Pan Chen, Jing Wang, Yanying Chen i Jiaxin Luo. "Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy". Endocrine Connections 8, nr 6 (czerwiec 2019): 754–63. http://dx.doi.org/10.1530/ec-19-0045.
Pełny tekst źródła